[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201791632A1 - Ингалятор сухого порошка, содержащий флутиказон пропионат и сальметерол ксинафоат - Google Patents

Ингалятор сухого порошка, содержащий флутиказон пропионат и сальметерол ксинафоат

Info

Publication number
EA201791632A1
EA201791632A1 EA201791632A EA201791632A EA201791632A1 EA 201791632 A1 EA201791632 A1 EA 201791632A1 EA 201791632 A EA201791632 A EA 201791632A EA 201791632 A EA201791632 A EA 201791632A EA 201791632 A1 EA201791632 A1 EA 201791632A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dry powder
dose
fluticasone propionate
user
fluticason
Prior art date
Application number
EA201791632A
Other languages
English (en)
Inventor
Мукул Далви
Си Ки Ти
Original Assignee
Тева Брэндид Фармасьютикал Продактс Ар Энд Ди, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55443303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201791632(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Тева Брэндид Фармасьютикал Продактс Ар Энд Ди, Инк. filed Critical Тева Брэндид Фармасьютикал Продактс Ар Энд Ди, Инк.
Publication of EA201791632A1 publication Critical patent/EA201791632A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A61M15/0006—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means
    • A61M15/0008—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means rotating by airflow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение предлагает ингалятор сухого порошка, содержащий сухое порошковое лекарственное средство, содержащее флутиказона пропионат, сальметерола ксинафоат и лактозный носитель; при этом доставляемая доза флутиказона пропионата на одно срабатывание ингалятора составляет менее чем 100 мкг и причем доза обеспечивает у пользователя FEVс поправкой на исходные показатели более чем 150 мл в течение 30 мин после приема дозы. Способ лечения пользователя включает в себя доставку пользователю сухого порошкового лекарственного средства, содержащего флутиказона пропионат, сальметерола ксинафоат и лактозный носитель; при этом доставляемая доза флутиказона пропионата на одно применение составляет менее чем 100 мкг и причем доза обеспечивает у пользователя FEVс поправкой на исходные показатели более чем 150 мл в течение 30 мин после приема дозы.
EA201791632A 2015-01-20 2016-01-20 Ингалятор сухого порошка, содержащий флутиказон пропионат и сальметерол ксинафоат EA201791632A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562105479P 2015-01-20 2015-01-20
PCT/US2016/014072 WO2016118589A1 (en) 2015-01-20 2016-01-20 Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat

Publications (1)

Publication Number Publication Date
EA201791632A1 true EA201791632A1 (ru) 2017-12-29

Family

ID=55443303

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791632A EA201791632A1 (ru) 2015-01-20 2016-01-20 Ингалятор сухого порошка, содержащий флутиказон пропионат и сальметерол ксинафоат

Country Status (19)

Country Link
US (2) US9415008B2 (ru)
EP (1) EP3247331A1 (ru)
JP (1) JP2018503687A (ru)
KR (1) KR20170103975A (ru)
CN (1) CN107530357A (ru)
AR (1) AR104771A1 (ru)
AU (2) AU2016209363B2 (ru)
BR (1) BR112017015353A2 (ru)
CA (1) CA2974125A1 (ru)
CL (1) CL2017001859A1 (ru)
CO (1) CO2017008395A2 (ru)
EA (1) EA201791632A1 (ru)
HK (1) HK1245125A1 (ru)
IL (1) IL253499A0 (ru)
MA (1) MA41378A (ru)
MX (2) MX2017009122A (ru)
PE (1) PE20171258A1 (ru)
TW (1) TW201628607A (ru)
WO (1) WO2016118589A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2863198T3 (es) * 2013-10-07 2021-10-08 Teva Branded Pharmaceutical Products R&D Inc Inhalador de polvo seco
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
KR102539907B1 (ko) * 2016-11-18 2023-06-05 노턴 (워터포드) 리미티드 전자 장치를 구비한 약물 전달 기구
CN110201280B (zh) * 2018-02-28 2021-07-30 张江 用于吸入给药装置的吸嘴和吸入给药装置
CN110201278B (zh) * 2018-02-28 2021-07-30 张江 用于吸入给药的药盒和吸入给药组合结构
CN110201281B (zh) * 2018-02-28 2021-08-06 张江 吸入给药装置和吸入给药组合结构
CN110064110A (zh) * 2019-05-29 2019-07-30 上海理工大学 一种容积旋钮式干粉储存吸入装置
GB2585206B (en) * 2019-07-01 2021-08-11 Merxin Ltd Portable inhaler

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
PE20020067A1 (es) * 2000-06-23 2002-02-05 Norton Healthcare Ltd Desaglomerador para inhalador de polvo seco accionado por la respiracion
TWI224514B (en) 2000-06-23 2004-12-01 Norton Healthcare Ltd Dose metering system for medicament inhaler
PE20020387A1 (es) * 2000-08-31 2002-06-24 Glaxo Group Ltd Uso de una combinacion de salmeterol y fluticasona
PT1337240E (pt) * 2000-11-30 2011-11-02 Vectura Ltd Método de fabrico de partículas para utilização numa composição farmacêutica
GB0124523D0 (en) * 2001-10-12 2001-12-05 Glaxo Group Ltd Pharmaceutical combination
AU2003279070A1 (en) 2002-09-30 2004-04-23 Acusphere Inc Sustained release porous microparticles for inhalation
US9114081B2 (en) * 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US20110135737A1 (en) * 2009-05-29 2011-06-09 Pearl Therapeutics, Inc. Compositions for respiratory delivery of active agents and associated methods and systems
US20110229437A1 (en) * 2009-09-17 2011-09-22 Mutual Pharmaceutical Company, Inc. Method of Treating Asthma with Antiviral Agents
GB0919465D0 (en) * 2009-11-06 2009-12-23 Norton Healthcare Ltd Airflow adaptor for a breath-actuated dry powder inhaler
EA201690641A1 (ru) * 2010-05-18 2016-08-31 Ивакс Фармасьютикалз Аэрлэнд Инкрементальный счетчик доз для ингалятора отмеренных доз
EP2571486A4 (en) * 2010-05-20 2013-12-04 Sun Pharma Advanced Res Co Ltd DRY POWDER INHALATION COMPOSITION
KR20130140358A (ko) * 2012-06-14 2013-12-24 한미약품 주식회사 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법
WO2014177520A1 (en) * 2013-04-29 2014-11-06 Sanofi Sa Inhalable pharmaceutical compositions and the inhaler devices containing them
ES2863198T3 (es) * 2013-10-07 2021-10-08 Teva Branded Pharmaceutical Products R&D Inc Inhalador de polvo seco
PE20170690A1 (es) * 2014-10-16 2017-05-25 Teva Branded Pharmaceutical Products Randd Inc Formulacion de polvo seco
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol

Also Published As

Publication number Publication date
IL253499A0 (en) 2017-09-28
PE20171258A1 (es) 2017-08-28
EP3247331A1 (en) 2017-11-29
JP2018503687A (ja) 2018-02-08
MX2021006751A (es) 2021-07-15
US9415008B2 (en) 2016-08-16
AU2021202784A1 (en) 2021-05-27
WO2016118589A1 (en) 2016-07-28
US20180015035A1 (en) 2018-01-18
CO2017008395A2 (es) 2018-01-05
HK1245125A1 (zh) 2018-08-24
AU2016209363B2 (en) 2021-02-04
CN107530357A (zh) 2018-01-02
US20160206559A1 (en) 2016-07-21
MA41378A (fr) 2017-11-28
CL2017001859A1 (es) 2018-04-06
CA2974125A1 (en) 2016-07-28
TW201628607A (zh) 2016-08-16
MX2017009122A (es) 2017-10-12
BR112017015353A2 (pt) 2018-01-16
AU2016209363A1 (en) 2017-08-24
AR104771A1 (es) 2017-08-16
KR20170103975A (ko) 2017-09-13

Similar Documents

Publication Publication Date Title
EA201791632A1 (ru) Ингалятор сухого порошка, содержащий флутиказон пропионат и сальметерол ксинафоат
EA201690738A1 (ru) Ингалятор сухого порошка
EP4269440A3 (en) Composition for treating il-6-related diseases
MX2015012760A (es) Composicion farmaceutica que comprende un activador de ampk y un agente serotonergico y metodos de uso de la misma.
MX2019012884A (es) Terapia de combinacion.
BR112019005168A2 (pt) composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente que sofre ou susceptível de sofrer de um distúrbio respiratório, para melhoria da estabilidade de uma composição farmacêutica e do desempenho de aerossolização de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica
EA201370162A1 (ru) Новая фармацевтическая композиция со слабым побочным эффектом, включающая противотуберкулезные препараты
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
MX2015015132A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
AU2018256668A1 (en) Combination therapy comprising an inhibitor of JAK, CDK and PIM
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MY185942A (en) Selected amide of y-hydroxybutyric acid and uses thereof in the treatment of alcohol misuse
BR112019005080A2 (pt) composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente sofrendo ou susceptível de sofrer de um distúrbio respiratório, para melhorar a estabilidade de uma composição farmacêutica, para aumentar o tempo de estabilização de uma composição farmacêutica, para melhorar o desempenho de aerossolização de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica.
BR112018006206A2 (pt) composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa
WO2016167605A3 (ko) 고혈압 치료제를 이용한 흡연 및 비흡연자의 폐암 억제 방법
PH12016500120A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
EA202091618A1 (ru) Композиция кетамина в виде сухого порошка для применения при лечении депрессии ингаляционным путем
SA520420369B1 (ar) تركيبة مسحوق جاف صيدلانية للاستنشاق تشتمل على هرمون درقي
TH173838A (th) เครื่องพ่นละอองยาผงแห้ง
AR102903A1 (es) Inhalador de polvo seco
UA105586U (ru) Способ лечения печеночной энцефалопатии
EA201991630A1 (ru) Соединение хиназолина
BR112019005120A2 (pt) composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente sofrendo ou susceptível de sofrer de um distúrbio respiratório, para melhorar a estabilidade de uma composição farmacêutica, para melhorar o desempenho de dispersão em aerossol após armazenamento de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica.
UY35901A (es) Nueva dosificación y formulación